After developing in the thymus, mature thymocytes upregulate sphingosine 1-phosphate receptor type 1 (S1P 1 ) and exit into the circulation to populate the naive T cell compartment. S1P 1 and its ligand, sphingosine 1-phosphate (S1P), are required for the egress of mature thymocytes 1 . FTY720, a small-molecule immunosuppressant being tested in clinical trials for the treatment of autoimmune disease, inhibits egress by modulating S1P 1 function 1 . Beyond the requirement for S1P 1 , little is understood about how T cells migrate from the thymus.
The cataract Shionogi (CTS) strain was initially isolated in the 1960s from a closed colony of ICR mice on the basis of its cataracts and microphthalmia 2 . The CTS strain was later established to have a defect in thymic egress 3 after it failed to reject major histocompatibility complex-disparate skin grafts 4 . The nature of this recessive defect, called 'peripheral T cell deficiency' (Ptcd), and its function in thymic egress have remained unclear.
Coronins are actin regulators found in all eukaryotes 5 . In addition to binding F-actin, coronin proteins associate with and inhibit the nucleation-promoting Arp2/3 complex. Seven coronin family members exist in mammals, including coronin 1A (Coro1A), which is expressed mainly in hematopoietic cells. Coro1A-deficient mice have fewer peripheral T cells due to more apoptosis 6, 7 , and one study has attributed this to an excessive accumulation of F-actin 6 . T cell migration is also reported to be defective 6, 7 , but this has been called into question 8 . Those last authors have also questioned whether Coro1A deficiency alters F-actin dynamics and instead link the greater apoptosis to a T cell antigen receptor (TCR) signaling defect 8 . These conflicting reports of Coro1A-deficient mice have complicated the understanding of the function of this actin regulator in T cell biology.
Here we report that Ptcd T cells had an intrinsic migration defect that impaired thymic egress and trafficking through lymph nodes. We 'narrowed' the Ptcd locus and identified a point mutation in the gene encoding Coro1A (Coro1a) that resulted in mislocalization of the protein in T cells and greater inhibition of Arp2/3 by Coro1A in biochemical assays. In a parallel effort to identify additional trafficking mutants by screening mice carrying N-ethyl-N-nitrosourea (ENU)-induced mutations for altered peripheral T cell numbers, we identified a strain with 90% less Coro1A and a phenotype similar to that of Coro1A-knockout mice. Comparison of Ptcd and Coro1A-deficient T cells allowed us to separate the defect in TCR-induced calcium signaling from the diminished thymocyte survival. In addition to yielding new alleles of Coro1a, our mouse forward-genetics approach led us to identify a T cell-deficient, B cell-sufficient and natural killer cell-sufficient (T -B + NK + ) patient with SCID who has Coro1A deficiency.
RESULTS

Ptcd is an intrinsic T cell-migration defect
To characterize the cellular basis of the Ptcd defect, we first backcrossed the Ptcd locus onto the C57BL/6 (B6) strain and confirmed the accumulation of mature single-positive (SP) thymocytes (CD69 lo CD62L hi ) and associated lower number of peripheral T cells ( Fig. 1a and Supplementary Fig. 1 online) . Irradiated wild-type mice that had been reconstituted with Ptcd bone marrow cells also had an accumulation of mature thymocytes and few circulating T cells (Fig. 1b) , whereas reciprocal bone marrow chimeras did not have such defects (Supplementary Fig. 2 online) . These results localized the Ptcd defect to a hematopoietic lineage-derived cell and indicated that impaired egress of mature thymocytes from the thymus is a pathogenic mechanism.
Although normal amounts of S1P 1 were expressed on Ptcd mature SP thymocytes (Fig. 1c) , S1P 1 function was impaired. In Transwell migration assays, Ptcd mature CD4 SP thymocytes were less efficient in migrating toward S1P than were cells from control heterozygous littermates (Fig. 1d) . The cells also migrated less efficiently toward the chemokines CCL21 and CXCL12. The response of Ptcd CD4 + CD8 + double-positive thymocytes to CXCL12 was similarly lower (Fig. 1e) , and the migration of naive Ptcd splenic T cells was impaired, whereas B cells migrated normally (Fig. 1f) . The expression of CCR7 and CXCR4, the respective chemokine receptors that recognize CCL21 and CXCL12, was similar in Ptcd and control cells ( Supplementary Fig. 3 online). These results indicate that T cells in Ptcd mice have a general, cell-intrinsic migration defect that impairs S1P 1 responsiveness and blocks thymic egress.
Ptcd T cells have entry, egress and motility defects To test for peripheral trafficking defects, we transferred Ptcd and control T cells together into wild-type recipients. At 1 h after transfer, the ratio of Ptcd T cells to control T cells was lower in peripheral and mesenteric lymph nodes and higher in blood (Fig. 2a) , which indicated that Ptcd cells were less efficient in entering lymph nodes. Next we tested lymph node egress with two approaches. First, we transferred Ptcd and control T cells together at a ratio of 3:1 to achieve equal proportions in the lymph nodes. At 24 h after transfer, we found a much lower proportion of Ptcd cells in lymph than in lymph nodes (Fig. 2b) , which was consistent with a diminished ability to exit into lymph. As an additional approach, we assessed the retention of Ptcd T cells in lymph nodes. After transferring Ptcd and control T cells, we blocked entry into lymph nodes for 20 h with integrin-neutralizing antibodies. Roughly 60% of Ptcd T cells were retained in the lymph nodes, compared with just 20% of control T cells (Fig. 2c) . These results collectively demonstrate that Ptcd T cells are defective in exiting lymph nodes. Two-photon microscopy of explanted lymph nodes from mice that had received fluorescence-labeled cells showed that whereas control cells moved at a median velocity of 9.5 mm/min, Ptcd cells moved at a lower median velocity of 6.6 mm/min ( Fig. 2d and Supplementary Movie 1 online). In addition, Ptcd cells had larger turning angles (Fig. 2e) , indicative of less-directed paths, and the cells failed to efficiently displace over time (Fig. 2f) . These results demonstrate that in addition to blocking thymic egress, the Ptcd defect impairs trafficking through lymph nodes.
Coro1a is mutated at the Ptcd locus The Ptcd locus has been mapped to a 10.9-megabase region of chromosome 7 containing over 300 open reading frames 9 . To refine the locus, we did a mapping cross between CTS and B6 mice, using thymocyte accumulation to phenotype mice (Fig. 3a) . We noted that the cataracts and microphthalmia were present in F 1 hybrids and failed to segregate together with the recessive Ptcd trait (data not shown), consistent with an early report that these eye traits are autosomal dominant 10 . After analyzing over 900 meiosis events, we further mapped the Ptcd locus to a critical interval of 950 kilobases (Fig. 3b) . This gene-rich interval contained 37 open reading frames, including Coro1a ( Supplementary Fig. 4 online). Coro1a was a likely candidate gene for Ptcd because of its abundance in T cells 11 and the association of coronin family molecules with actin-based motility 5 . Sequencing of Ptcd DNA showed a G-to-A mutation in exon 2 of Coro1a (Fig. 3c) , which resulting in a nonconservative glutamic acid-to lysine substitution at residue 26 in the b-propeller domain of the protein (Coro1A E26K ; Fig. 3d ). This residue was conserved in all annotated Coro1A sequences and the charge of the residue was also conserved in a large number of orthologs ( Supplementary Fig. 5 online) and was in a surface-exposed loop 12 adjacent to a region that in the close relative Coro1B has been indicated to be an actin-binding site 13 . Immunoblot analysis showed that the abundance of Coro1A in total thymocytes did not vary between Ptcd and controls (Fig. 3e) .
To exclude the possibility that substitutions other than Coro1A E26K were responsible for the Ptcd phenotype, we tested for genetic complementation by crossing Ptcd mice with Coro1a +/-mice. As expected, the Coro1a wild-type allele complemented Ptcd defects in T cell lymphopenia and F-actin accumulation, whereas the Coro1a-null allele failed to complement ( Supplementary Fig. 6a ,b online). In addition, mature thymocyte numbers were slightly higher in Ptcd/-mice than in Ptcd/+ mice ( Supplementary Fig. 6c ). Although these studies do not exclude the possibility that the Ptcd interval contains additional genetic modifiers, the inability of the Coro1a-null allele to 'rescue' several of the Ptcd defects provides strong evidence that the Coro1A E26K substitution results in the Ptcd phenotype.
ENU-mutant Koyaanisqatsi is a Coro1A hypomorph
In parallel to the studies reported above, we did an ENU-mutagenesis screen to identify regulators of lymphocyte trafficking and egress. We initially identified 'Koyaanisqatsi' (Koy) as a recessive mutant strain of mice with a circulating T cell deficiency (Fig. 4a) . Further characterization of Koy mice showed that they had fewer mature thymocytes and peripheral T cells ( Fig. 4b and Supplementary Fig. 7 online). In Transwell migration assays, Koy thymocytes and naive T cells migrated much less efficiently than did cells from littermate control mice (Fig. 4c) . These findings in Koy mice, along with more phalloidin staining of Koy mature thymocytes (Fig. 4d) , resembled those reported for Coro1a -/-mice generated by gene targeting 6 . After sequencing Koy DNA, we identified an A-to-T substitution in exon 7 of Coro1a (Fig. 4e ) that resulted in an aspartic acid-to-valine substitution at residue 278. This residue is located at a contact surface predicted to be critical for the proper assembly and stability of Coro1A 12 , and immunoblot analysis of total thymocytes showed that Koy cells had roughly one tenth as much Coro1A as wild-type cells had (Fig. 4f) . These data indicate that Koy is a hypomorphic mutant of Coro1A. Survival and Ca 2+ flux of Coro1A mutants Direct comparison of Ptcd, Koy and Coro1a -/-mice confirmed that the E26K substitution was not a phenocopy of the Coro1A-deficient state. Although Ptcd mutants had an accumulation of mature thymocytes (Fig. 1a) , Coro1A-deficient mice had fewer mature thymocytes (Fig. 4b ) due to reduced cell survival 6 . Analysis of cell viability by measurement of loss of mitochondrial membrane potential (Fig. 5a ) and annexin V staining (Fig. 5b) showed that mature thymocytes from Ptcd mice were similar to those from wild-type control mice, whereas mature thymocytes from Coro1a -/-mice were less viable. However, Ptcd splenic T cells had a survival defect similar to that of Coro1a -/-cells (Fig. 5a,b) .
A published study has attributed the survival defect of Coro1a -/-T cells to 'downstream' effects of excessive accumulation of F-actin 6 . Consistent with that interpretation, mature Ptcd thymocytes had only slightly more F-actin, as assessed by phalloidin staining (Fig. 5c) , whereas mature Coro1a -/-thymocytes and the similarly apoptosisprone Ptcd and Coro1a -/-splenic T cells all had approximately twofold more phalloidin staining (Fig. 5c) . However, the correlation between F-actin accumulation and less viability did not seem to hold true for Ptcd/-T cells, as they had more phalloidin staining similar to that of Coro1a -/-T cells and yet were not fewer in number in the thymus ( Supplementary Fig. 6 ). A study has suggested that the lower viability of Coro1a -/-cells reflects a requirement for Coro1A in TCR-induced Ca 2+ flux rather than in F-actin regulation 8 . However, Ptcd and Coro1A-deficient mature CD4 SP thymocytes showed similar defects in Ca 2+ flux after CD3 crosslinking (Fig. 5d) . Furthermore, both Ptcd and Coro1A-deficient cells showed minimal defects compared with wild-type cells after combined crosslinking of CD3 and CD4 (Fig. 5d) , a treatment that may more closely mimic major histocompatibility complex class II-peptide engagement 14 . These findings dissociate the function of Coro1A in TCR-induced Ca 2+ signaling from its function in thymocyte viability but leave unclear whether Coro1A acts through F-actin regulation or by some other mechanism to promote T cell survival.
Coro1A E26K is mislocalized in Ptcd T cells Coro1B regulates F-actin dynamics at the leading edge of migrating fibroblasts 15 , and we found that in migrating wild-type T cells, Coro1A was situated in F-actin-rich and Arp2/3-rich leading-edge protrusions (Fig. 6a,b) . The distribution of Coro1A E26K in migrating Ptcd T cells was considerably altered and little of the protein could be detected at the leading edge (Fig. 6a) , whereas Arp2/3 continued to concentrate in this region (Fig. 6b) . Coro1A E26K also similarly mislocalized when expressed in fibroblasts ( Supplementary Fig. 8 online) , which indicated an intrinsic failure to distribute at the leading edge.
Real-time live cell imaging showed that protrusions from migrating Ptcd T cells were irregularly shaped and often larger in size than protrusions from wild-type cells, consistent with a failure to properly regulate the actin cytoskeleton ( Fig. 6c and Supplementary Movies 2-4 online). We noted similarly dysmorphic protrusions from Ptcd/-compound mutant T cells ( Supplementary Fig. 6d ).
The short in vitro survival of Coro1A-deficient T cells made assessments difficult, but these cells seemed more severely compromised in their migration than Ptcd T cells were (Supplementary Movie 5 online). These results collectively establish that Coro1A E26K fails to distribute correctly in migrating T cells and that the cells have aberrant shape regulation.
Coro1A E26K enhances Arp2/3 inhibition To understand the biochemical effect of the E26K substitution, we first assessed the ability of Coro1A to bind F-actin. In cosedimentation assays, Coro1A E26K associated normally with F-actin (Fig. 6d) . In contrast, Arp2/3 coimmunoprecipitated more Coro1A E26K than wildtype Coro1A from cell lysates (Fig. 6e) . The corresponding substitution in Coro1B also resulted in more association with Arp2/3 ( Supplementary Fig. 9 online). Consistent with more interaction with Arp2/3, Coro1A E26K was more efficient than wild-type Coro1A in inhibiting Arp2/3 activity in actin-polymerization assays (Fig. 6f) .
To examine how this biochemical gain-of-function substitution manifested as a recessive Ptcd allele, we analyzed T cells from Ptcd/+ and Ptcd/-mice. As expected, the Coro1A distribution in Ptcd/-T cells (Fig. 6g) was similar to that in Ptcd/Ptcd T cells (Fig. 6a) . In Ptcd/+ T cells, Coro1A was both present at and mislocalized away from the leading edge (Fig. 6g) . These results suggest that in Ptcd/+ cells, wild-type Coro1A can access the leading edge to regulate actin dynamics. In summary, these biochemical studies indicate that the highly conserved Glu26 residue in Coro1A is important for the regulation of Arp2/3.
Coro1A is deficient in a T -B + NK + patient with SCID After finding that point mutations in Coro1a resulted in severe T lymphopenia in both Ptcd and Koy mice, we sought to determine whether CORO1A mutations could also be responsible for human cases of primary T cell immunodeficiency with undefined etiologies. Thus, we sequenced CORO1A in DNA from 16 SCID patients lacking mutations in previously recognized genes associated with T -B + NK + SCID. Although we failed to detect any CORO1A mutations in 15 samples, we did identify a single patient with a two-nucleotide deletion in exon 3 (deletion of CT between nucleotides 248 and 249 in the coding DNA sequence; Fig. 7a ) that resulted in a frame shift and premature stop codon in the area encoding the Coro1A b-propeller domain (with the first amino acid affected by the frame shift being a substitution of arginine for proline at position 83, and the creation of a new reading frame that ended at the first stop codon at position 10 (with arginine now amino acid 1)). Consistent with a destabilizing truncation, immunoblot analysis of Epstein Barr virus (EBV)-immortalized B lymphoid cell lines derived from the patient's peripheral blood showed an absence of Coro1A protein (Fig. 7b) . When this patient was 13 months old, she was hospitalized with a severe varicella infection after vaccination; she was later diagnosed as an atypical T -B + NK + patient with SCID and was treated by allogeneic bone marrow transplantation. We found that her father was heterozygous for the two-base pair deletion in CORO1A but her mother and sister were not (Fig. 7a) .
To assess the gene-copy number of CORO1A in the patient, we did quantitative PCR of genomic DNA with nonoverlapping primers spanning intron 1 through exon 11 of CORO1A and noted 50% less product relative to that of a healthy control (Fig. 7c) . In contrast, signals for the human genes encoding S1P 1 , on chromosome 1, and coronin 7, located telomeric to CORO1A on chromosome 16p, did not differ from the quantitative PCR signal in control cells. Along with reports of copy-number variation in chromosome 16p11.2, where CORO1A is located [16] [17] [18] , these data suggest that our patient, who inherited a two-base pair paternal deletion in one allele of CORO1A, also has deletion of the other CORO1A allele.
DISCUSSION
Using a forward-genetics approach, we have identified a unique Coro1a allele that allowed us to establish a requirement for this actin-regulatory protein in the egress of T cells from the thymus and lymph nodes. Two-photon microscopy showed that Coro1A was needed for normal T cell motility in the lymph node, and in vitro motility studies indicated its involvement in regulating cell shape. Moreover, this mutation identified a site on Coro1A critical for Arp2/3 regulation and for controlling Coro1A distribution in the cell. Finally, we demonstrated that Coro1A deficiency in a human was associated with a peripheral T cell deficiency of sufficient severity to cause T -B + NK + SCID.
The identification of a critical function for Coro1A in egress from the thymus and lymph nodes provides evidence that migration from these tissues depends on proper regulation of Arp2/3-mediated actin branching, most likely in response to S1P. The protein mDia1, a member of the formin family of actin-nucleating proteins that promote the formation of unbranched actin filaments, is also needed for thymic egress 19 . Thus, the formation of both correctly branched as well as unbranched actin networks seems to be required for exit from this organ. The function of mDia1 in lymph node egress has not been assessed. The small G proteins Rac and Cdc42 induce activation of the Wiskott-Aldrich syndrome protein-Arp2/3 system and, consistent with our results here, the Rac activator Dock2 is needed for lymph node egress 20 . Although the function of Dock2 in thymic egress has not been determined, given the need for Coro1A, we anticipate that Dock2 is also involved. Lymphocyte protrusions initiate diapedesis 21 , and our findings suggest that Coro1A-dependent control of actin may be critical in the formation of protrusions during T cell egress. The requirement for Arp2/3-mediated actin branching for T cellmigration responses to chemoattractants has been supported by findings obtained with cells deficient in Dock2, Wiskott-Aldrich syndrome protein and Wiskott-Aldrich syndrome protein-interacting protein 20, 22, 23 as well as Coro1A-deficient cells 6, 7 . Our results obtained with Ptcd T cells add to those findings and suggest an important function for Coro1A-mediated Arp2/3 regulation in the control of T cell shape. A published study has argued that F-actin dynamics are unaltered in Coro1A-deficient T cells, although cell migration in response to chemoattractants was not examined 8 . The basis for these discrepant findings is unclear, but it seems possible that the very poor survival of Coro1A-deficient naive T cells and their consequent depletion from T cell preparations relative to effector and/or memory T cells confounded some of the comparisons. In our studies here, we were careful to exclude both dead cells and effector or memory cells from our analysis of naive T cells. Although the migration of Ptcd T cells was much lower in vitro and in the lymph node, it was not absent, and this might explain the continued ability of the Ptcd mouse thymus to organize into cortex and medulla 3 . It seems likely that the lack of notable defects in Ptcd and Coro1A-deficient B cells is due to redundancy with other coronin family members, and this adds to other data establishing differences in requirements for B cell and T cell motility 19, 24, 25 . Whether substitutions in Coro1A or other actin-regulatory molecules cause defects in common lymphoid progenitors remains to be determined. Although bone marrow chimera-reconstitution efficiencies were similar for Ptcd and control donors, our studies did not formally address whether the entry of early thymic precursors is impaired. Future studies should include competition assays with mixed-bone marrow chimeras to evaluate the proportion of Ptcd-derived cells in bone marrow and thymus. Leukocyte migration in lymphoid tissue has been described as phases of force-generating actin protrusions followed by myosin-dependent contractions 26 that aid the squeezing of the cell nucleus through threedimensional matrices. In this context, it is notable that Ptcd T cells not only had large and dysmorphic protrusions but also failed to elongate their nuclei. Thus, remodeling of the actin cytoskeleton by Coro1A may contribute to both protrusion and contraction during the migration of T cells through lymphoid tissues.
The mechanism by which coronin proteins inhibit Arp2/3-mediated actin branching is complex and incompletely understood. Although several studies have shown that coronin proteins are able to directly bind Arp2/3 and possibly inhibit function before F-actin binds 27, 28 , work with Coro1B in fibroblasts suggests that it acts by displacing Arp2/3 from actin branch points 29 . We have demonstrated that a Coro1A surface proximal to the predicted F-actin-binding region 13 was involved in Arp2/3 regulation. Our findings emphasize the importance of characterizing the highly conserved Glu26-containing surface of the type I coronin subfamily in future structure-function studies focusing on how an oligomeric coronin complex dislodges Arp2/3 from F-actin. The failure of Coro1A E26K to localize normally to the leading edge of migrating cells has identified what may be another level of coronin regulation. Further studies are needed to determine whether interactions with the cofilin phosphatase slingshot 5 or other still-unknown coronin-binding partners are altered by the substitution.
Coro1A deficiency caused a substantial defect in T cell survival, but the basis for this effect is not yet resolved. Although the Ptcd is an important allelic comparison that 'disconnected' the survival and Ca 2+ -flux defects, the greater phalloidin staining of Ptcd/-mature thymocytes also failed to support the idea of a simple correlation between survival and F-actin accumulation. The possibility remains that Coro1A directly affects cell survival independently of effects on F-actin, and analysis of additional Coro1A substitutions may yield new allelic insights. The continued ability of Ptcd thymocytes to maintain nearly normal total cellular F-actin despite mislocalization of Coro1A might be explained by an ongoing association of low but sufficient amounts of Coro1A E26K to achieve partial regulation of Arp2/3 at the leading edge, or it might reflect correspondingly greater actin-debranching and depolymerization in the cell body. Alternatively, the in vitro assay for examining colocalization of Arp2/3 and Coro1A may not accurately reflect how these proteins distribute in vivo in migrating thymocytes. The similar partial deficiencies in TCR-induced Ca 2+ flux in Coro1A E26K and Coro1a -/-T cells are in agreement with emerging evidence that an intact actin cytoskeleton is important for Ca 2+ flux 30 . However, our finding that CD3-CD4 cocrosslinking led to equivalent Ca 2+ flux in wild-type, Coro1A E26K and Coro1a -/-thymocytes, along with a published report of normal proliferation of Coro1a -/-T cells stimulated by antigen-presenting cells 6 , suggests that Coro1A may have a limited function in TCR signaling during encounters with cognate antigen. We anticipate that single-cell analysis of the release of Ca 2+ stores and the activity of Ca 2+ release-activated channels in Ptcd and Coro1A-deficient mature thymocytes and T cells, along with similar studies of T cells with other defects in actin-regulatory proteins, will add to the understanding of how the actin cytoskeleton contributes to calcium signaling.
An important challenge of studies of mouse models is 'translation' of the findings to humans. The identification of a patient with a peripheral T cell deficiency who lacks expression of Coro1A suggests that Coro1A has similar functions in humans and mice. Although the human X-linked Wiskott-Aldrich syndrome has long associated actin biology with hematopoietic cell dysfunction, the Coro1A-deficient patient we studied here allowed us to link regulation of the actin cytoskeleton with SCID 31 . T -B + NK + SCID has been defined before by mutations resulting in impaired TCR or interleukin 7 receptor signaling 32 . Other forms of SCID involve defects in purine metabolism, DNA recombination or cytokine signaling 33 . Mutations in genes involved in these pathways result in apoptosis through purine toxicity, deficient cytokine signaling or failure to rearrange a signaling-competent antigen receptor. Given the results of our study of Coro1A deficiency, we can also include apoptosis via actin dysregulation as a cause of SCID. A report classifying a Coro1a-null allele as an autoimmune-suppression locus in mice 7 is consistent with the idea that Coro1A defects cause immunodeficiency. We predict that substitutions in other hematopoietic cell-specific actin-associated molecules will be found to cause SCID. Because the pericentromeric segment of human chromosome 16 that contains CORO1A is prone to copynumber variation [16] [17] [18] , we also anticipate that additional cases of patients with lower T cell function will involve CORO1A mutations.
METHODS
Mice, ENU mutagenesis and bone marrow chimeras. B6 and B6-CD45.1 mice were from the Jackson Laboratories, the National Cancer Institute or a colony maintained at the University of California, San Francisco. UBC-GFP mice were from Jackson Laboratories. Cataract-Shionogi (CTS/Shi) mice were from TGC. Ptcd was backcrossed six to ten generations onto the B6 strain with singlenucleotide polymorphism (SNP) markers as described below. Coro1a -/-mice, which were backcrossed ten generations with B6 mice, were generated as described 6 . Koy mice were identified by an ENU-mutagenesis screen done as described 34 with B6 mice in a colony maintained at the Australian National University. Male B6 mice were treated with three doses, 1 week apart, of 100 mg ENU (Sigma) per kg body weight in 10% (vol/vol) ethanol in citrate buffer, pH 5.0, to produce G 0 mice. After a refractory period of 8 weeks, these G 0 males were mated with B6 females to generate G 1 offspring. Two unrelated G 1 mice were crossed, producing G 2 mice, which were then intercrossed to yield G 3 mice. Screening of these G 3 mice by flow cytometry identified the Koy phenotype. All mice were housed in specific pathogen-free conditions, and all protocols were approved by the Institutional Animal Care and Use Committee of the University of California, San Francisco, or the Animal Experimentation Ethics Committee of Australian National University. Bone marrow chimeras were generated with 2 Â 10 6 to 3 Â 10 6 bone marrow cells from donor mice transplanted intravenously into lethally irradiated congenic host mice. Chimeras were given prophylactic water containing antibiotics and were analyzed 8-12 weeks after transplantation.
Flow cytometry, intracellular staining and measurement of Ca 2+ flux. Polyclonal antibody to S1P 1 (anti-S1P 1 ) has been described 35 . Phalloidinfluorescein isothiocyanate was from Sigma. Indo-1 was from Invitrogen. Kits for intracellular staining and annexin V staining were from BD Biosciences. The JC-1 mitochondrial membrane potential assay kit was from Cayman. All other antibodies used for flow cytometry were from BD Biosciences, Invitrogen, eBiosciences or BioLegend. Ca 2+ -flux assays were adapted from published methods for thymocytes 14 . Cells were loaded for 30 min at 30 1C with Indo-1 in the presence of biotinylated anti-CD3 (2C11; BD), fluorescein isothiocyanateanti-CD8 (53-6.7; BD) and Alexa Fluor 647-anti-CD4 (M4-5; BD). Thymocytes were additionally stained with phycoerythrin-anti-CD62L (Mel14; BD) and splenocytes were additionally stained with phycoerythrin-anti-CD44 (IM7; BD). Cells were washed and kept on ice until analysis. For crosslinking of CD3 and CD4, cells were additionally pretreated for 5 min with biotinylated anti-CD4 (RM4-4; BD). Cells were mixed with prewarmed media containing propidium iodide for exclusion of dead cells and were warmed to 37 1C. Baseline Ca 2+ concentrations were assessed for 30 s before crosslinking with streptavidin (50 mg/ml; Pierce). All flow cytometry was done on a FACSCalibur or an LSRII (BD).
Purification of recombinant protein. Coronin recombinant protein was expressed and purified with a mammalian expression system as described for Coro1B 15 . Purified protein was quantified by absorbance at 280 nm and the predicted extinction coefficients of 62,910 M -1 cm -1 (Coro1A) and 65,890 M -1 cm -1 (Coro1B).
Immunoprecipitation. Cells were washed twice with PBS and were lysed with a KCl buffer (20 mM HEPES, pH 7.0, 100 mM KCl, 0.5% (vol/vol) Nonidet P-40, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 10 mg/ml of 1,10-phenanthroline, 10 mg/ml of aprotinin, 10 mg/ml of leupeptin, 10 mM sodium fluoride and 2 mM sodium orthovanadate). Lysates were cleared for 5 min at 13,000g and were incubated with 0.5 mg primary antibody for 16 h at 4 1C, followed by the addition of 20 ml of a slurry of ImmunoPure-immobilized protein A/G beads (Pierce) and further incubation for an additional hour at 4 1C. Immune complexes were collected, were washed three times with KCl buffer, were separated by SDS-PAGE and were transferred to a polyvinylidene difluoride membranes (Bio-Rad) for immunoblot analysis.
Actin-assembly assay. Arp2/3-nucleation reactions induced by the verprolin homology, cofilin homology, acidic domain were done as described 15 : recombinant coronin and Arp2/3 (20 nM) were mixed in MKEI-50 buffer (20 mM imidazole-KOH, pH 7.0, 50 mM KCl, 2 mM MgCl 2 and 1 mM EGTA) and were incubated for 5 min at 25 1C; reactions were initiated by the simultaneous addition of 1.5 mM actin (5% labeled with pyrene, primed for 90 s with 1 mM EGTA and 0.1 mM MgCl 2 ) and 1 nM glutathione S-transferase-verprolin homology, cofilin homology, acidic domain. The delay between mixing of reactants and recording of fluorescence was 15 s. Fluorescence was converted to the molar concentration of F-actin according to the fluorescence of completely polymerized actin (24 h after reaction) and unpolymerized actin, with the assumption a critical concentration of 0.1 mM.
Immunoblot analysis. Lysates from mouse thymocytes and human EBVimmortalized cell lines were prepared in radioimmunoprecipitation buffer (1% (vol/vol) Nonidet P-40, 0.5% (wt/vol) sodium deoxycholate, 0.1% (vol/ vol) SDS, 50 mM Tris, pH 8.0, 150 mM NaCl and 0.02 NaN 3 ) and were resolved by PAGE (NuPage; Invitrogen), then were transferred (XCell; Invitrogen) to Immobilon-FL membranes (Millipore), were blocked and probed with LICOR buffer and were analyzed on an Odyssey infrared imager (LICOR). Anti-Coro1A (07-493) was from Upstate Biotechnology, anti-actin (A2066) was from Sigma, and secondary IRDye antibody (611-730-127) was from Rockland.
Transwell migration. Thymocytes and splenocytes collected in migration medium (RPMI medium (Cellgro) supplemented with 10 mM HEPES, pH 7.2 (Cellgro), 100 U/ml of penicillin-streptomycin (Cellgro) and 0.5% (vol/vol) fatty acid-free BSA (Calbiochem)) were used for assays of migration through Transwells (5 mm; Corning). For analysis of migration to S1P, thymocytes were assayed immediately after isolation. For analysis of migration to chemokines, thymocytes or splenocyte samples in which erythrocytes were lysed were resensitized in migration media for 30 min at 37 1C. S1P (Sigma), the human chemokine SDF-1a (Peprotech) and mouse CCL21 and CXCL13 (R&D Systems) were used at various concentrations.
Adoptive cell transfer and treatment. Thymocytes were labeled with the cytosolic dye CFSE (carboxyfluorescein diacetate succinimidyl diester) or CellTracker orange CMTMR ((5-(and-6)-(((4-chloromethyl)benzoyl)amino)-tetramethylrhodamine); Molecular Probes) as described 36 . For adoptive transfer, mice were injected intravenously with about 1 Â 10 7 to 3 Â 10 7 cells in about 0.3 ml media. For homing assays, mice were analyzed 1 h after transfer. For assays of peripheral egress, mice were analyzed 24 h after transfer or were treated intravenously for 20 h with entry-blocking antibodies and were analyzed after 44 h. Antibodies used for in vivo entry blockade have been described 37 .
Two-photon microscopy. Thymocytes from donor mice were isolated and were labeled with CellTracker orange CMTMR (Invitrogen-Molecular Probes) as described 38 , then were injected intravenously into B6 recipient mice along with thymocytes from UBC-GFP mice. After 12-24 h, inguinal lymph nodes were isolated for two-photon microscopy, and axillary and brachial lymph nodes were isolated for flow cytometry. Flow cytometry confirmed that over 90% of CMTMR + cells in lymph nodes were mature SP thymocytes (CD4 + CD8 -CD69 lo CD62L hi or CD4 -CD8 + CD69 lo CD62L hi ). Explants were prepared as described 39 . Inguinal lymph nodes were perfused with RPMI medium (Cellgro) at 36-37 1C, were aerated with 95% O 2 and 5% CO 2 and were imaged from the cortical side of the lymph node through the capsule. A 'custom' two-photon microscope system was used for imaging, with the 5-W MaiTai TiSapphire laser (Spectra-Physics) tuned to an excitation wavelength of 890 nm. Images were captured with Video Savant software (IO Industries). For time-lapse imagery, 30-36 planes 3 mm apart were collected every 20 s. Each xy plane spanned 240 mm Â 288 mm at a resolution 0.6 mm per pixel. Data were further processed with MetaMorph software (Molecular Devices). Imaris software (Bitplane AG) was used for three-dimensional volume rendering and cell tracking. Matlab software was further used to calculate cell velocities, turning angles and displacement. Statistical significance was evaluated with a paired two-tailed Student's t-test.
Genetic mapping, SNP analysis, human samples and sequencing. CTS/Shi mice were crossed with B6 mice to generate an F 1 generation. The Ptcd locus was mapped with mutant F 2 progeny of F 1 intercrosses, F 1 mice backcrossed to nonparental CTS mice, or mutant F 2 mice crossed with nonparental F 1 mice. Mice were phenotyped by analysis of thymocyte subset frequencies by flow cytometry. Genomic DNA was isolated from tail tissue (Wizard Genomic kit; Promega) and the Amplifluor HT kit (Chemicon, Millipore) and an ABI7300 (Applied Biosystems) were used according to the manufacturers' instructions for SNP reactions. Mapping SNPs were selected on the basis of polymorphisms between B6 mice and BUB/J, a strain closely related to CTS/Shi. SNP primers were designed on the AssayArchitect website. Patients with SCID and their parents, where available, were enrolled with informed content in studies with Institutional Review Board-approved protocols for determination of genotype and genotype-phenotype correlations. Blood samples were immortalized with EBV to create B cell lines. Human genomic DNA was isolated from buccal swabs or EBV-immortalized lines with a Puregene kit (Gentra Systems). An ABI7300 was used for quantitative PCR of genomic DNA. Human CORO1A and mouse Coro1a exons and surrounding splice regions were amplified by PCR from genomic DNA, were resequenced and were analyzed on 4Peaks software (mekentosj) relative to the reference human genomic and cDNA sequences NM_007074 and NM_007074.2, respectively (primers, Supplementary Table 1 online).
Brightfield and immunofluorescence microscopy. For fixed immunofluorescence imaging, 1 Â 10 6 to 2 Â 10 6 lymphocytes from peripheral and mesenteric lymph nodes were seeded onto chambered coverslips (Lab-tek, Nunc) precoated with recombinant mouse intercellular adhesion molecule 1-Fc fragment (10 mg/ml; R&D Systems) and were allowed to settle and migrate for 1 h at 37 1C in the presence of CCL21 (1 mg/ml; R&D Systems) in RPMI medium (Cellgro) supplemented with 1% (vol/vol) FCS (Invitrogen), 10 mM HEPES, pH 7.2 (Cellgro) and 100 U/ml of penicillin-streptomycin. Cells were then fixed with 4% (wt/vol) paraformaldehyde (Sigma) and were made permeable with 0.5% (vol/vol) Triton-X100 (Sigma) in PBS. Coverslips were then stained with a combination of the following: anti-Coro1A (rabbit polyclonal antibody; 07-493; Millipore, Upstate) or anti-p34Arc (rabbit polyclonal antibody to the Arp2/3 subunit p34; 07-227; Millipore; Upstate), fluorescein isothiocyanateconjugated phalloidin (Sigma), Alexa Fluor 647-conjugated anti-CD4 (RM4-5; BD), Alexa Fluor 647-conjugated anti-CD8 (53-6.7; BD), biotinylated goat anti-rabbit (BD), streptavidin-indocarbocyanine (Jackson Immuno) or 4,6-diamidino-2-phenylindole (Molecular Probes). The z-stacks were captured on an Axiovert Z1 (Zeiss) and were deconvoluted with Axiovision Software (Zeiss). For real-time imaging, 5 Â 10 5 lymphocytes from peripheral and mesenteric lymph nodes were stained with phycoerythrin-conjugated anti-CD19 (1D3; BD) and Alexa Fluor 647-conjugated anti-CD4 and anti-CD8 and were seeded on intercellular adhesion molecule-coated chambered coverslips with CCL21 as described above with the addition of 0.1% (wt/vol) NuSieve GTG Low Melt agarose (FMC BioProducts) and 4,6-diamidino-2-phenylindole. Cells were maintained at 37 1C and 5% CO 2 during the 3-4 h of imaging in an environmentally controlled stage on an Axiovert Z1. Each 5-minute movie was generated at time-lapse intervals of 10 s, with assembly of a z-stack at each time point from six brightfield xy views with a z-step of 0.5 mm. After the time lapse, a fluorescence image was captured to identify live T cells. Movies and images were processed with Axiovision (Zeiss) and were exported for annotation and splicing with AfterEffects (Adobe).
Note: Supplementary information is available on the Nature Immunology website.
